- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01155141
Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
Study Overview
Detailed Description
EXPERIMENTAL TREATMENT: Patients with biopsy proven FSGS will be treated with ACTH in an open-label pilot study of tolerability and efficacy. The investigators will recruit 18-20 patients to complete this study, over 2 years.
ACTH therapy: Patients will receive H.P. Acthar gel IM or SQ, initially at 40 IU SQ every week for 16 weeks of therapy. All patients will be treated to goal BP of <140/90mmHg with all patients treated with ACEi or ARB therapy as tolerated. H2 receptor blockade or proton pump inhibitor therapy will also be offered all patients. Dose will be titrated up to 160 IU SQ every week, if at 1 month the patient has had no substantial reduction in proteinuria, no deterioration of blood pressure and no development of hyperglycemia as well as no serious adverse events felt to be related to the medication.
CLINICAL OUTCOME: Patients will be followed for the primary outcome of remission of proteinuria. This will be defined as partial remission when the proteinuria is reduced below 50% of the initial, pre treatment value and as complete remission when the proteinuria is reduced to < 0.5 g/g or <500 mg/day on a 24 hour urine sample. Secondary outcomes will include effects on eGFR, effects on glucose levels, effects on blood pressure (total doses of antihypertensive medications and absolute changes in blood pressure) and on immune status. Outcomes will be determined by looking at 3 month and 6 month values of urine protein and eGFR following initiation of treatment.
IMMUNOLOGIC TESTING: In order to further assess the role of immunologic perturations on FSGS and the effect of ACTH on the immune system, all patients will bank blood and urine before the start of the study for cytokine analysis, RNA, DNA, protein and protoarray testing.
MONITORING AND SAFETY: All patients will undergo full informed consent per the Stanford Institutional Review Board. Contact numbers will be provided and study staff will be available at all times in case of any medical emergencies. All patients will continue with routine health monitoring with a minimal of monthly assessments. A comprehensive interview will be undertaken to assess for side effects, complete physical exams will be accomplished including vital signs, CBC, clinical chemistries (including electrolytes, creatinine, glucose and liver function tests), urine for protein and creatinine and fasting lipid profiles every 3 months. Also at screening and baseline.
PATIENT WITHDRAWAL/TERMINATION OF STUDY: Patients will be closely monitored, as detailed above. Patients may voluntarily leave the study at any time, although every effort will be made to follow their clinical course and monitor for safety issues and possible benefits of therapy. Patient will be monitored for adverse events. Patients with severe adverse events will be evaluated for the relatedness of their event to the study medication. If the event is considered severe and possibly or probably related to the study medication, the medication will be discontinued and the patient will continue to be monitored. In the case the adverse event is possibly related, the medication may be restarted, if the investigator and subject agree. For patients with probably related severe adverse events, study treatment will be discontinued however, the investigators will still follow the patient to see if the course of their underlying disease was modified by treatment. As this is an open label, pilot study, no data safety monitoring board is felt to be necessary. If drug related SAEs develop in more than 20% of patients, the study will be submitted back to the IRB to determine if it should continue.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Biopsy proven FSGS
- 2. Ability to consent and complete study evaluations
- 3. Greater than 2g/day of proteinuria
- 4. No contraindications to treatment with corticosteroids or ACTH
- 5. Women of childbearing potential will agree to use effective forms of birth control throughout this study
Exclusion Criteria:
- 1. Known secondary cause of FSGS
- 2. Receiving active immune therapy (within 90 days)
- 3. Pregnancy
- 4. Creatinine >2.5 mg/dl
- 5. Uncontrolled HTN (>180/100mm Hg)
- 6. Diabetes
- 7. Acute or chronic infection
- 8. Severe comorbidity (active coronary, cerebrovascular disease, cancer, psychiatric disease)
- 9. Age < 16, >65 years
- 10. Evidence of untreated tuberculosis (+PPD or Ellispot Gold testing)
- 11. A known contraindication to ACTH. Corticotropin is considered contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, or sensitivity to proteins of porcine origin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: No arms
There are no arms to this study.
All patients receive drug (H.P. Acthar Gel)
|
Patients were treated with 40 units subcutaneously (SC) weekly for 2 weeks, then dose increased to 80 units SC weekly for 2 weeks followed by 80 units SC twice weekly to complete 16 weeks of therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
24 Hour Proteinuria
Time Frame: Baseline - Month 6
|
Baseline - Month 6
|
Serum Creatinine
Time Frame: Baseline - Month 6
|
Baseline - Month 6
|
Protein/Creatinine Ratio
Time Frame: Baseline - Month 6
|
Baseline - Month 6
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
eGFR
Time Frame: Baseline - Month 6
|
Baseline - Month 6
|
Weight
Time Frame: Baseline - Month 6
|
Baseline - Month 6
|
Systolic Blood Pressure
Time Frame: Baseline - Month 6
|
Baseline - Month 6
|
Diastolic Blood Pressure
Time Frame: Baseline - Month 6
|
Baseline - Month 6
|
Glucose
Time Frame: Baseline - Month 6
|
Baseline - Month 6
|
Total Cholesterol
Time Frame: Baseline - Month 6
|
Baseline - Month 6
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Richard Lafayette, Stanford University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SU-08182009-3600
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Diseases
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
University of North Carolina, Chapel HillLantheus Medical ImagingCompletedChronic Kidney Diseases | Cystic Kidney DiseaseUnited States
-
SanofiTerminatedCongenital Cystic Kidney DiseaseGermany, Spain, United States, Australia, Belgium, Japan, Korea, Republic of, Netherlands
-
University of UtahNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingHemodialysis | Kidney Disease, Chronic | Kidney Failure | Dialysis | Diabetic | End-stage Kidney Disease | Kidney Dysfunction | Non-diabeticUnited States
-
Pang PengGuangdong Provincial Hospital of Traditional Chinese MedicineUnknownEnd-Stage Kidney Disease | Chronic Kidney FailureChina
-
RenJi HospitalUnknownKidney Diseases,CysticChina
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
George Washington UniversityCareDx; VirginiaBio Analytics, LLCTerminatedKidney Diseases | Kidney Failure, Chronic | Kidney Transplant Infection | Kidney Transplant Rejection | Kidney Injury | Kidney Disease, Chronic | Kidney Failure | Kidney Failure, Acute | Kidney Transplant; Complications | Kidney IschemiaUnited States
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
Clinical Trials on H.P. Acthar Gel
-
Ocular Immunology and Uveitis FoundationUnknownUveitis, Posterior | Vasculitis RetinalUnited States
-
Fiechtner, Justus J., M.D., P.C.CompletedLupus Erythematosus Systemic ExacerbationUnited States
-
University of Maryland, BaltimoreMallinckrodtCompleted
-
Mayo ClinicMallinckrodtCompletedIdiopathic Membranous NephropathyUnited States, Canada
-
Fiechtner, Justus J., M.D., P.C.MallinckrodtUnknownPsoriatic ArthritisUnited States
-
The Cleveland ClinicMallinckrodtCompletedDermatomyositis | Juvenile DermatomyositisUnited States
-
MallinckrodtCompletedArthritis, RheumatoidUnited States, Puerto Rico, Mexico, Peru, Argentina
-
Columbia UniversityMallinckrodtCompletedTreatment Resistant Nephrotic SyndromeUnited States
-
Dent Neuroscience Research CenterCompletedChronic MigraineUnited States
-
MallinckrodtCompleted